Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is undervalued on EV/EBITDA.
Target Price
The average target price of BGBIO.OL is 1.9 and suggests 62% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc